COSMOS study seeks definitive answers on cell phones and cancers
An international consortium involving the UK, Denmark, Sweden, Finland, and the Netherlands has launched a large epidemiological study in the hopes of uncovering definitive conclusions about the health risks believed to be associated with the use of cell phones.
The project, which goes by the acronym COSMOS (International Cohort Study of Mobile use and Health) is scheduled to last 20-30 years.
COHORT
200,000 mobile phone users at least 18 years old.
ENDPOINTS
Risk of …
- Cancers
- Benign tumors
- Neurological diseases
- Cerebro-vascular diseases
- Change in occurrence of specific symptoms over time (i.e. headache, sleep disorders)
Organizations who have accorded COSMOS highest research priority
- The World Health Organization
- EMF-Net
- The EU Scientific Committee on Emerging and Newly Identified Health Risks (SCENHIR)
- The Advisory Group on Non-Ionising Radiation
- The UK Mobile Telecommunications and Health Research (MTHR-2) programme
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
